• Citer

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

par Kirschbrown, Whitney W.P.;Kågedal, Matts;Wang, Bei;Lindbom, Lars;Knott, Adam;Mack, Rachelle;Monemi, Sharareh;Nijem, Ihsan;Girish, Sandhya;Freeman, Christie;Fumagalli, Debora ;McConnell, Robin;Jerusalem, Guy;Twelves, Chris;Baselga, José;Von Minckwitz, Gunter;Bines, Jose;Garg, Amit X
Référence Cancer chemotherapy and pharmacology, 83, 6, page (1147-1158)
Publication Publié, 2019-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Auteur:	Kirschbrown, Whitney W.P.; Kågedal, Matts; Wang, Bei; Lindbom, Lars; Knott, Adam; Mack, Rachelle; Monemi, Sharareh; Nijem, Ihsan; Girish, Sandhya; Freeman, Christie; Fumagalli, Debora; McConnell, Robin; Jerusalem, Guy; Twelves, Chris; Baselga, José; Von Minckwitz, Gunter; Bines, Jose; Garg, Amit X
Informations sur la publication:	Cancer chemotherapy and pharmacology, 83, 6, page (1147-1158)
Statut de publication:	Publié, 2019-06
Sujet CREF:	Cancérologie
	Toxicologie pharmaceutique
	Pharmacologie
Mots-clés:	Drug–drug interactions
	Exposure–response
	Pertuzumab
	Pharmacokinetics
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0344-5704
	info:doi/10.1007/s00280-019-03826-1
	info:scp/85065192416
	info:pmid/30976844